Overview
A category-defining health-technology company, the pioneer of an entirely new class of FDA-authorised, software-based prescription medicine and backed by investors including SoftBank's Vision Fund, Temasek, and Novartis, set out to go public in a transaction valuing it at roughly $1.6 billion. Taking a first-of-its-kind company public is as much a communication challenge as a financial one. Public-market investors had to understand a brand-new category of medicine, and understand it quickly, across a compressed roadshow.
The Mandate
VERBED was the partner trusted to develop the materials behind that roadshow and the go-public transaction. The work was translation and conviction at the highest tier: making a complex, category-defining story clear and credible to public-market investors evaluating it on a tight timeline, to the standard of execution a multi-billion-dollar transaction demands.
Outcome
The company completed its transaction and debuted on the public markets at a pro forma equity value of approximately $1.6 billion, taking a pioneering new category public and demonstrating VERBED's work behind the materials for a multi-billion-dollar offering.
A public company with billions in market cap at stake
Investor materials for a multi-billion-dollar consumer VC
A confident board update for an uncertain market
From overlooked to 3x oversubscribed
A first fund worthy of a global name
LP materials that raised $190M, 30% over target
From first raise to strategic exit
The M&A package that created millions in accretive value
From wholesaler to scalable platform
The $1.6B presentation
Partnership conversations at the industry's biggest week
A global rebrand and product launch
A decade as an extension of the executive team
A brand from scratch for a Super Bowl champion
Carrying authority into new clinical ground
AGM preparation while the CEO closed multiple acquisitions
